Antisynthetase Syndrome Without Lung Disease Yet: Surveillance Versus Pre-Emptive Therapy
A single patient with anti-Jo-1 antisynthetase syndrome and a currently clean chest scan. The disagreement is over how much to treat the lung disease she doesn't have yet.
Kara D., 38, has run marathons for most of her adult life, and the first sign something was wrong was a training pace she couldn't explain away — followed within weeks by symmetric swelling and pain in both hands, rough, cracked skin across her fingertips and palms, and a growing difficulty climbing the stairs to her apartment. Anti-Jo-1 antibody testing came back positive, with a creatine kinase of 1,800, confirming antisynthetase syndrome: the inflammatory polyarthritis, the myositis, and the hyperkeratotic "mechanic's hands" skin change that, together, are close to the textbook presentation. What she does not have, at least not yet, is the complication that drives most of this disease's real morbidity — her HRCT at diagnosis was normal, and pulmonary function testing showed no restrictive pattern at all.
That distinction is the entire question in front of the team, because antisynthetase syndrome's own natural history doesn't guarantee it stays that way: interstitial lung disease in anti-Jo-1-positive patients frequently develops after the joint and muscle disease is already apparent, sometimes considerably later, and it is specifically early, non-fibrotic lung disease that responds well to treatment — once fibrosis is established, the same therapy does far less. Which of her own features should raise the alarm is less intuitive than it looks. In Marie and colleagues' anti-Jo-1 series, the patients who had interstitial lung disease were distinguished from those who did not by more frequent mechanic's hands — and by lower creatine kinase levels, not higher. Her cracked, hyperkeratotic palms therefore sit on the side of that comparison associated with lung involvement, while her creatine kinase of 1,800 points, if anything, the other way. Neither is a validated way to predict what will happen to one patient, and the group whose ILD deteriorated was marked out by different things again: a usual-interstitial-pneumonia pattern on scan, respiratory muscle involvement, and age over 55, none of which describes a 38-year-old with a clean HRCT. The honest position is that she has one feature pointing toward the complication and one pointing away from it, which is an argument for looking rather than for treating.
At diagnosis, a clean chest scan and a well-known pattern
Her HRCT is normal and her PFTs show no restrictive pattern — she does not have interstitial lung disease today. Treating her active joint and muscle disease with prednisone and methotrexate is standard, proportionate care. Most of the literature supporting more aggressive combination immunosuppression in antisynthetase syndrome describes patients who already have ILD — that's a different population than hers, and adding an agent she doesn't yet need would expose her to real side effects for a problem that may never arrive.
I'm not going to argue against starting methotrexate for the disease she has right now. But I want to reframe the actual ask — it isn't "add a drug today," it's "commit to surveillance now."
Anti-Jo-1-positive patients have a well-described pattern of developing lung disease after the joint and muscle presentation, sometimes considerably later, and a scheduled interval of PFTs and HRCT — not symptom-triggered alone — is the only way to catch it while a treatment window still exists, since early, non-fibrotic disease responds to therapy in a way established fibrosis does not. "She doesn't have ILD today" answers a different question than "does she need surveillance," and conflating the two risks missing a diagnosis that often presents without symptoms severe enough to prompt an unscheduled visit. And there's a problem with the drug you've just proposed that bears directly on the test I'm asking for: methotrexate pneumonitis presents as a non-specific interstitial pneumonia pattern on HRCT, and non-specific interstitial pneumonia is also the commonest pattern of anti-Jo-1 lung disease. Start her on methotrexate and any new ground-glass I find at twelve months is ambiguous between the disease I'm surveilling for and the drug we gave her — with opposite management implications, since one calls for stopping the drug and the other for escalating immunosuppression. I'm not vetoing methotrexate. I'm saying that if we use it, today's normal HRCT is not just a reassuring baseline, it is the comparator that will have to carry that distinction later, and the surveillance schedule needs to be written knowing that.
I'd take the surveillance point further, and I'll start by correcting something I would have said myself a few years ago. The intuition that a CK of 1,800 marks her as high-risk for lung disease is backwards: in Marie's anti-Jo-1 series the patients who had ILD ran lower creatine kinase levels than those who didn't, not higher. What did track with ILD in that comparison was mechanic's hands, which she has.
So I'd still argue for mycophenolate now rather than waiting for surveillance to catch something, but on her skin findings rather than her enzyme level — and I'll say plainly that this rests on a group-level association in a retrospective series, not a validated way to predict her individual risk, and that her own CK cuts against my case rather than for it.
Agreed: start prednisone and methotrexate for the active joint and muscle disease, decline adding mycophenolate today given the absence of current interstitial lung disease, and commit to a defined surveillance schedule — pulmonary function testing and HRCT at fixed intervals, not merely if she becomes symptomatic — specifically because of her anti-Jo-1 status, with today's normal HRCT retained as the explicit baseline against which any future change must be read, given that methotrexate's own pulmonary toxicity mimics the pattern being watched for.
Not agreed: the myositis specialist still believes her mechanic's hands justifies broader upfront coverage now rather than waiting for surveillance to catch a future problem, and would revisit mycophenolate sooner than a wait-for-a-positive-finding plan implies if her skin findings worsen further even without any change on HRCT. He accepts that her creatine kinase argues against him and declines to rest on it. The pulmonologist's separate reservation — that methotrexate's own NSIP-pattern toxicity will complicate reading any future scan — was recorded rather than resolved, with the group agreeing only that today's baseline HRCT makes it manageable.